Alnylam Pharmaceuticals/ US02043Q1076 /
2024-05-21 9:59:55 PM | Chg. -0.55 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
149.61USD | -0.37% | 18,720 Turnover: 2.8 mill. |
-Bid Size: - | -Ask Size: - | 151.26 | 147.83 |
GlobeNewswire
05-14
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
GlobeNewswire
04-23
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held M...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmace...
GlobeNewswire
02-29
Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease
GlobeNewswire
02-28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmace...
GlobeNewswire
02-20
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
GlobeNewswire
02-02
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
2023-12-13
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
GlobeNewswire
2023-12-11
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeuti...
GlobeNewswire
2023-11-28
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics...
GlobeNewswire
2023-11-14
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmace...